Search

Your search keyword '"Spire, B"' showing total 52 results

Search Constraints

Start Over You searched for: Author "Spire, B" Remove constraint Author: "Spire, B" Topic antiretroviral therapy, highly active Remove constraint Topic: antiretroviral therapy, highly active
52 results on '"Spire, B"'

Search Results

1. A generalized additive model to disentangle age and diagnosis-specific cohort effects in psychological and behavioral outcomes in people living with HIV: the French cross-sectional ANRS-VESPA2 survey.

2. Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir.

3. Treatment interruption in HIV-positive patients followed up in Cameroon's antiretroviral treatment programme: individual and health care supply-related factors (ANRS-12288 EVOLCam survey).

4. Patient profiles as organizing HIV clinicians' ART adherence management: a qualitative analysis.

5. Brief Report: Prolonged Viral Suppression Over a 12-Year Follow-up of HIV-Infected Patients: The Persistent Impact of Adherence at 4 Months After Initiation of Combined Antiretroviral Therapy in the ANRS CO8 APROCO-COPILOTE Cohort.

6. Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course.

7. Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme: early findings of the ANRS 12249 TasP trial in rural South Africa.

8. Twelve-year mortality in HIV-infected patients receiving antiretroviral therapy: the role of social vulnerability. The ANRS CO8 APROCO-COPILOTE cohort.

9. Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon.

10. French HIV experts on early antiretroviral treatment for prevention: uncertainty and heterogeneity.

11. Impact of HCV treatment and depressive symptoms on adherence to HAART among HIV-HCV-coinfected patients: results from the ANRS-CO13-HEPAVIH cohort.

12. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.

13. Assessing adherence to antiretroviral therapy in randomized HIV clinical trials: a review of currently used methods.

14. Adherence to and effectiveness of highly active antiretroviral treatment for HIV infection: assessing the bidirectional relationship.

15. Adherence as a predictor of sexual behaviors in people living with HIV/AIDS during the first year of antiretroviral therapy in rural Cameroon: data from Stratall ANRS 12110/ESTHER trial.

16. Satisfaction with care in HIV-infected patients treated with long-term follow-up antiretroviral therapy: the role of social vulnerability.

17. Implementing operational research to scale-up access to antiretroviral therapy for HIV infection: lessons learned from the Cameroonian experience.

18. Similar short-term efficacy of antiretroviral therapy in patients infected with HIV B and non-B subtype strains in france.

19. Prolonged medically recorded treatment interruptions among HIV-infected patients on highly active antiretroviral therapy with controlled viremia: when physicians have to juggle patient negotiation and guidelines.

20. Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data.

21. Effect of anxiety symptoms on adherence to highly active antiretroviral therapy in HIV-infected women.

22. Withdrawal symptoms as a predictor of mortality in patients HIV-infected through drug use and receiving highly active antiretroviral therapy (HAART).

23. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.

24. [Anhedonia and depressive symptomatology among HIV-infected patients with highly active antiretroviral therapies (ANRS-EN12-VESPA)].

25. Prevalence and predictors of deterioration of a trustful patient-provider relationship among HIV-infected persons treated with antiretroviral therapy.

26. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST).

27. Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8).

28. Time perspective and quality of life among HIV-infected patients in the context of HAART.

29. Health related quality of life among both current and former injection drug users who are HIV-infected.

30. The effect of depressive symptoms at ART initiation on HIV clinical progression and mortality: implications in clinical practice.

31. Heterogeneous response to HAART across a diverse population of people living with HIV: results from the ANRS-EN12-VESPA Study.

33. Vulnerability, unsafe sex and non-adherence to HAART: evidence from a large sample of French HIV/AIDS outpatients.

34. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.

35. Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase.

36. Management of HIV-related stigma and adherence to HAART: evidence from a large representative sample of outpatients attending French hospitals (ANRS-EN12-VESPA 2003).

37. [Outcome of HIV-infected patients after 5 years of antiretroviral therapy including a protease inhibitor: the Aproco/Copilote Cohort].

38. Health-related quality of life and patient-provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment.

39. Drug resistance and adherence to HIV/AIDS antiretroviral treatment: against a double standard between the north and the south.

40. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study.

41. [Economic and socio-behavioural issues related to highly active antiretroviral therapies for HIV infection: the contribution of social science research].

42. Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study.

43. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users.

44. Health-related quality of life after 1 year of highly active antiretroviral therapy.

45. Nonadherence among HIV-infected injecting drug users: the impact of social instability.

46. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach.

47. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy.

48. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort.

49. Impact of short-term adherence on virological and immunological success of HAART: a case study among French HIV-infected IDUs.

50. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART.

Catalog

Books, media, physical & digital resources